SEC Filing Summary: Rexahn Pharmaceuticals, Inc. (Form 8-K)
Business Context and Reporting Period
Date of Report: May 16, 2005 (Earliest event: May 13, 2005)
Company: Rexahn Pharmaceuticals, Inc. (formerly Corporate Road Show.Com Inc.)
Event: Completion of a reverse merger with Rexahn, Corp. The transaction was accounted for as a reverse acquisition, with Rexahn, Corp. treated as the accounting acquirer. The company ceased its historical business operations and adopted Rexahn's business plan as a clinical-stage biopharmaceutical company focused on cancer therapies.
Key Financial Metrics
Revenue: No product revenue generated to date. Minimal revenue recognized from a research agreement with a minority shareholder ($75,000 annually) and interest income ($57,463 in 2004).
Profitability: The company is not profitable and has never been profitable.
Net Losses:
- 2004: $3,273,442
- 2003: $2,775,075
- 2002: $1,181,157
Cash Flow: Net cash used in operating activities was $2,880,625 in 2004. Total cash and cash equivalents were $1,015,979 as of December 31, 2004.
Debt: In February 2005, the company completed a private placement of $3.85 million in convertible notes.
Liquidity: Management believes current cash resources (including February 2005 financing) are sufficient for approximately 12 months of minimum planned operations. Auditors have issued a "going concern" qualification due to recurring losses.
Material Changes vs. Prior Period
- Corporate Structure: The company changed its name from Corporate Road Show.Com Inc. to Rexahn Pharmaceuticals, Inc. and reincorporated in Delaware following a 1-for-100 reverse stock split and merger.
- Ownership: Former Rexahn stockholders now hold approximately 91.8% of the outstanding common stock (41,538,630 shares total).
- Management: The board of directors was reconstituted. Frank Ferraro (former sole director/officer) resigned and settled his employment agreement. Dr. Chang H. Ahn was appointed Chairman and CEO.
- Business Focus: Shifted from a corporate road show business to a biopharmaceutical company developing signal transduction inhibitors for cancer.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance:
- Capital Needs: The company expects to spend a minimum of $4.75 million over the next 12 months ($3M for RX-0201 trials, $1.5M general expenses, $250k rent). Total funding needs could aggregate $20 million through Q1 2007 to fully execute the development plan.
- Product Pipeline:
- RX-0201: Akt inhibitor in Phase I clinical trials (expected completion Q3 2005). Orphan drug designated for five cancers.
- RX-0047: HIF inhibitor in pre-clinical stage; Phase I expected Q1 2006.
- RX-0183 & RX-3117: Small molecule candidates in pre-clinical stage; Phase I expected Q3 2006 and Q4 2006, respectively.
Risks and Contingencies:
- Going Concern: Substantial doubt exists regarding the ability to continue as a going concern without additional financing.
- Regulatory Approval: No drug candidates have received FDA approval. The FDA has not approved any antisense oligonucleotide (ASO) compounds to date.
- Market Liquidity: Stock trades on the OTC Bulletin Board and may be classified as a "penny stock," limiting liquidity and resale ability.
- Third-Party Reliance: The company relies entirely on third parties for manufacturing and clinical trial execution.
Unusual Items:
- Settlement Agreement: Issued 500,000 shares to former officer Frank Ferraro in settlement of employment and debt obligations.
- Reverse Merger: The transaction structure resulted in the former shell company (CPRD) being the legal survivor, but the financial statements reflect the historical operations of Rexahn, Corp.
Investor Verification Checklist
- Verify the sufficiency of the $3.85 million convertible note financing to cover the projected $4.75 million minimum operating burn rate for the next 12 months.
- Confirm the status and enrollment numbers of the Phase I clinical trial for RX-0201 at Georgetown University.
- Review the terms of the convertible notes issued in February 2005, specifically the floating conversion price mechanism.
- Assess the impact of the "penny stock" designation on the ability to raise future capital or for shareholders to sell shares.
- Monitor the timeline for pre-clinical toxicology studies for RX-0047, RX-0183, and RX-3117, as delays could accelerate cash burn.